Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains

Investors who believe that blue-chip stocks mean boring haven’t been paying close attention in 2026. This year, several stocks that have often lagged the S&P 500 are having stellar years, rewarding buy-and-hold investors.

To be fair, growth-hungry investors often overlook blue-chip stocks for practical reasons. These are older companies at a mature stage in their business cycle with solid balance sheets that provide predictable gains for investors. However, predictability can also limit the kind of upside growth investors typically chase.

Why has the script flipped for several blue-chip stocks in 2026? Some of it is sector rotation as investors look for gains outside of the artificial intelligence (AI) trade. Energy and biotechnology have been among the sectors investors have looked at. But even some consumer-facing stocks are performing well.

The stock price return is only one part of the story. Each of these stocks offers an attractive and growing dividend. Together, those dividends and share-price gains can support long-term compounding.

Coca-Cola Stock Delivers Strong Returns and a Growing Dividend

The Coca-Cola Co. NYSE: KO is a blue-chip stock that’s been made iconic by legendary investor Warren Buffett, who is famously associate with the company is has often spoken about drinking Coca-Cola. Buffett appears to like the product almost as much as he likes the company. Coca-Cola has been a staple in the portfolio of Berkshire-Hathaway NYSE: BRK.B for decades.

The attributes that attracted Buffett to KO remain in place today. The company has a strong brand; it delivers consistent growth and a growing dividend.

Over the last 10 years, KO has delivered a total return of around 177%, including reinvested dividends. In 2026, the stock has also outperformed the S&P 500, with shares up about 25% through early September before dividends.

Coca-Cola is a Dividend King, having increased its dividend for 64 consecutive years. Its dividend currently yields 2.41% with a payout of $2.12 per share annually.

Coca-Cola has a more diversified portfolio in 2026 than when Berkshire first bought the stock. That’s one reason that the company raised its full-year outlook despite lingering concerns about the health of lower-income consumers and the impact of GLP-1 drugs on the company’s core soft-drink business.

Chevron Stock Rides Energy Tailwinds and a Growing Dividend

Many energy stocks, particularly those in the oil and gas industry, have been outperforming the S&P 500 in 2026. One of the best examples is Chevron Corp. NYSE: CVX. The integrated oil company has tailwinds from its existing portfolio, which is heavily concentrated in the Permian Basin, along with the benefits of integrating its completed merger with Hess.

The company also has an established presence in Venezuela, where it recently expanded its position and outlined plans for additional investment and production growth.

Critics may argue that Chevron, like many oil stocks, is enjoying a cyclical tailwind fueled by geopolitical events. But that’s only part of the story. The current infrastructure buildout in the United States will span the rest of this decade and likely beyond. And while renewables may be the future, oil is still very much part of the present.

Like Coca-Cola, Chevron is part of the Berkshire Hathaway portfolio. One reason is the company’s growing dividend and commitment to share buybacks. The company is a Dividend Aristocrat, having increased its dividend for 38 consecutive years. In addition to an attractive 3.34% yield, Chevron pays $7.12 per share annually.

CVX is up nearly 40% in 2026, more than three times the S&P 500’s gain through early September. Including dividends, the stock’s total return is even stronger.

Merck Stock Benefits From Oncology Growth and a Strong Pipeline

Merck & Co. NYSE: MRK rounds out this group of blue-chip stocks that have outperformed the S&P 500 in 2026. The company is best known for its blockbuster oncology drug, Keytruda.

It’s hard to minimize the impact of Keytruda on Merck’s financials. The drug, which is approved for several types of cancer across 44 indications and 19 tumor types, accounts for over 55% of the company’s pharmaceutical sales.

That's why investors are eyeing the company’s strategy for managing the patent cliff for Keytruda, which begins for some indications in 2028. One reason for optimism is the company’s deep pipeline.

That includes the drug it’s developing with Moderna NASDAQ: MRNA, which delivered positive top-line data in a Phase 3 study in August. This will help position Merck in the emerging field of personalized medicine, particularly in oncology.

MRK is up over 40% in 2026, with dividends pushing its total return above that level to over 43%. The company’s dividend yields 2.35% and pays $3.40 per share annually. Merck has increased that dividend for 14 consecutive years.

Should You Invest $1,000 in CocaCola Right Now?

Before you consider CocaCola, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CocaCola wasn't on the list.

While CocaCola currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here